Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vertex Pharmaceuticals Inc Issues FY 2013 Revenue Guidance In Line With Analysts' Estimates


Tuesday, 29 Jan 2013 04:01pm EST 

Vertex Pharmaceuticals Inc announced that for fiscal 2013, it expects total revenues to be in the range of $1.10 billion to $1.25 billion, including full year 2013 KALYDECO net revenues of $280 million to $320 million. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.14 billion for fiscal 2013. 

Company Quote

54.65
1.12 +2.09%
25 Nov 2014